Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.
about
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarctionAdenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarctionVasodilators in the treatment of patients with acute myocardial infarction undergoing percutaneous coronary interventionNo reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarctionShort-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trialsA randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6-month follow-upThe role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarctionStudy of the possible medical and medication explanatory factors of angiographic outcomes in patients with acute ST elevation myocardial infarction undergoing primary percutaneous intervention.The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised cProspective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes.Treating and preventing no reflow in the cardiac catheterization laboratory.Effect of Intravenous Administration of Liposomal Prostaglandin E1 on Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions.Management of 'no-reflow' complicating reperfusion therapy.Effects of intravenous diltiazem in a rat model of experimental coronary thrombotic microembolism.The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary interventionPrevention and treatment of no-reflow.No-reflow: again prevention is better than treatment.New strategies for the management of no-reflow after primary percutaneous coronary intervention.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiPharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?The challenges and impact of microvascular injury in ST-elevation myocardial infarction.Intracoronary adenosine versus intravenous adenosine during primary PCI for ST-elevation myocardial infarction: which one offers better outcomes in terms of microvascular obstruction?The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry.Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade.Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon
P2860
Q24187926-36A99AEB-9293-4ED2-B2A1-5097F287C456Q24202298-285A11AB-DECD-4E01-839E-B4EFEC974E35Q24234883-DE57E335-9AA4-41EF-8318-30D19A545686Q26740252-F9BB6157-1EF8-4519-8E9D-3129468889EFQ27013629-863251FA-A127-41DC-8B31-9E83A2482781Q28480797-EBBCF1DF-6F14-4EFA-B9A8-C8A10D7E6EDEQ33555475-1DD569D8-121F-47AF-8A67-1674E687D81CQ34198009-D1258EDB-51E9-457C-99BB-15BD4467E551Q34305843-041684F6-23EC-48C5-9BEF-9DF5B51555F6Q35772485-D802D1CF-FC26-451F-8E99-96EFE7D6BDACQ36302125-C8848BFC-479C-4193-B471-89CBC90A2726Q36797852-A9198B87-6BBF-420A-B235-A2E06EB1E447Q37145715-5F59676E-FD6C-49F8-BB30-7C6BFC8F130DQ37152013-347AF50E-BCEE-4038-8B81-D608EAB97D52Q37231298-FDA335C6-B51F-4383-B673-5029AC88B96DQ37431525-B96E6440-B00B-494F-9248-1AAD74BB18B9Q37779094-B38C9735-6E8D-4B60-B87F-3BBB2A87F85CQ37788437-7F6973A9-B967-49E9-9C75-74C4875488EBQ37880139-17FA8241-28C0-4B53-B9FF-FA69945A9209Q37953885-25D7B99F-38FE-4ADF-B47C-4B3752DD36FCQ38102885-99576EDB-9D35-42DF-AA0C-293AA90A2446Q38543451-C3077A7A-7604-409D-8E9A-C7D203F1AE5EQ38705817-46C7C4E8-FC66-4488-91DE-033766BC5B82Q39769940-91EF72C0-A8FE-4269-992C-E0F9F5237D65Q42830474-CC02E319-5883-4BEC-AB4C-790A5AF07929Q46662897-1434CBBE-4920-467D-A84B-881C2DABFE43Q54296892-B8501A0C-2B04-4777-9447-1FDC2F0C82A3Q58263433-FF141E92-770A-47B7-9215-EE57B2C3EE6C
P2860
Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Intracoronary verapamil for re ...... r acute myocardial infarction.
@en
Intracoronary verapamil for re ...... r acute myocardial infarction.
@nl
type
label
Intracoronary verapamil for re ...... r acute myocardial infarction.
@en
Intracoronary verapamil for re ...... r acute myocardial infarction.
@nl
prefLabel
Intracoronary verapamil for re ...... r acute myocardial infarction.
@en
Intracoronary verapamil for re ...... r acute myocardial infarction.
@nl
P2093
P356
P1476
Intracoronary verapamil for re ...... r acute myocardial infarction.
@en
P2093
Gerald S Werner
Helmuth Kuehnert
Klaus Lang
P304
P356
10.1002/CCD.10375
P577
2002-12-01T00:00:00Z